1971BMJOpen access

Hyperviscosity syndrome.

Taisuke Sato, Hirokazu Sugiyama

Open full text 8 citations

Abstract

Common clinical manifestations of the hyperviscosity syndrome are bleeding from mucosal membrane, retinopathy, visual disturbance and neurological disorders. These changes can be lethal, and early recognition is important for the proper therapy. Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein. These patients were currently treated with the combination of plasmapheresis and cytotoxic drugs. Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country. Recent studies have revealed plasmapheresis make blood flow smooth from the standpoint of blood flow dynamics.

Open-access reader

About this research paper

What this paper is about

Common clinical manifestations of the hyperviscosity syndrome are bleeding from mucosal membrane, retinopathy, visual disturbance and neurological disorders. These changes can be lethal, and early recognition is important for the proper therapy. Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein. These patients were currently treated with the combination of plasmapheresis and cytotoxic drugs. Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country. Recent studies have revealed plasmapheresis make blood flow smooth from the standpoint of blood flow dynamics.

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Common clinical manifestations of the hyperviscosity syndrome are bleeding from mucosal membrane, retinopathy, visual disturbance and neurological disorders. These changes can be lethal, and early recognition is important for the proper therapy. Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein. These patients were currently treated with the combination of plasmapheresis and cytotoxic drugs. Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country. Recent studies have revealed plasmapheresis make blood flow smooth from the standpoint of blood flow dynamics.

Key concepts: Plasmapheresis, Hyperviscosity syndrome, Hyperviscosity, Multiple myeloma, Medicine, Blood viscosity, Intensive care medicine, Surgery

Related papers

Back to paper searchBrowse research topicsOriginal source
Hyperviscosity syndrome. — Research Paper | ScholarLens